Form 4: PTC Therapeutics CEO Awarded Significant Equity Grants

PTC Therapeutics CEO Matthew B. Klein received 63,000 restricted stock units and 157,500 stock options as part of his compensation package.

Summary

• Matthew B. Klein, Chief Executive Officer and Director of PTC Therapeutics, Inc. (PTCT), was granted 63,000 shares of common stock in the form of Restricted Stock Units (RSUs) on January 2, 2026.
• These RSUs will vest in four equal annual installments, commencing on January 2, 2027.
• Klein also received 157,500 stock options with an exercise price of $76.74 per share, granted on January 2, 2026.
• The stock options vest over four years, with 25% vesting on January 2, 2027, and an additional 6.25% vesting at the end of each successive three-month period thereafter, starting April 2, 2027.
• Following these transactions, Klein beneficially owns 405,132 shares of common stock and 157,500 stock options.
• The reported common stock beneficial ownership includes 257 shares acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.

Sentiment

Score: 7

Explanation: The filing reports significant equity grants to the CEO, which is generally a positive signal as it aligns management's interests with shareholders for long-term value creation. It's a routine compensation disclosure, not an operational update.

Positives

• The significant equity grants to the Chief Executive Officer align his long-term financial interests with those of the shareholders, promoting sustained performance.
• The multi-year vesting schedules for both RSUs and stock options demonstrate a commitment to long-term value creation and executive retention.

Future Outlook

The equity grants with multi-year vesting schedules indicate a long-term commitment from the Chief Executive Officer to the company's performance and strategic objectives, aligning his incentives with future shareholder value creation.

Industry Context

This filing is a standard disclosure of executive compensation through equity grants, a common practice in the biotechnology and pharmaceutical industry to incentivize leadership and align their interests with long-term company performance.

Comparison to Industry Standards

• Not applicable for this type of filing, which details individual executive compensation rather than company performance or project outcomes.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial incentives with shareholder interests, potentially leading to more focused efforts on long-term stock performance.
• Employees: The grants are part of executive compensation, which can influence overall compensation philosophy and morale within the company.

Next Steps

• First vesting of Restricted Stock Units on January 2, 2027.
• First 25% vesting of stock options on January 2, 2027.
• Subsequent quarterly vesting of stock options beginning April 2, 2027.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, CEO Compensation, Equity Grant, Restricted Stock Units, Stock Options, Matthew B. Klein